- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06388720
Den kliniska effektiviteten och säkerheten för intravesikal Mitomycin-C och Gemcitabin sekvensiell terapi (IMGeS)
En studie för att bedöma den kliniska effektiviteten och säkerheten av intravesikal mitomycin-C och gemcitabin sekventiell terapi hos patienter med högrisk icke-muskelinvasiv blåscancer (NMIBC) som inte svarar på BCG-terapi
The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Phase 2 clinical, multi-institutional, open assignment prospective study
Primary Outcome Measures:
1-year recurrence-free survival period in high-risk groups after sequential injection of Mitomycin-c 40 mg/20 ml and Gemcitabine 2000 mg/50 ml in non-muscle invasive bladder cancer patients in BCG-free high-risk groups.
Secondary Outcome Measures:
Progression Free Survival (PFS), Cystectomy free survival (CFS), Cancer specific survival (CSS), Overall survival (OS) and safety after Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml treatment in non-muscle invasive bladder cancer patients in BCG-free high-risk groups.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Ho Kyung Seo, MD
- Telefonnummer: 82-31-920-1678
- E-post: seohk@ncc.re.kr
Studera Kontakt Backup
- Namn: Eui Hyun Jung, Ph.D
- Telefonnummer: 82-31-920-2451
- E-post: jeh0315@ncc.re.kr
Studieorter
-
-
-
Goyang-si, Sydkorea
- Rekrytering
- National Cancer Center
-
Huvudutredare:
- Ho Kyung Seo, MD
-
Kontakt:
- Ho Kyung Seo
- Telefonnummer: 82-31-920-1678
- E-post: seohk@ncc.re.kr
-
Underutredare:
- Eui Hyun Jung, Ph.D
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- a patient over the age of 20
- Patients who are willing and able to complete a written test subject consent/approval for this examination.
- Histologically confirmed high-risk NMIBC (according to AUA guidelines; High-grade T1 disease, any recurrent high-grade Ta, high-grade Ta >3 cm, high-grade Ta that is multifocal, any carcinoma in situ, any BCG failure in high-grade patients, any variant histology, any lymphovascular invasion, and any high-grade prostatic urethral involvement) with prior BCG therapy.
- The most recent bladder examination/TURBT must be performed within 8 weeks before the initial administration of the trial treatment. Patients with high risk NMIBC who received proper BCG treatment but did not respond to BCG
- Patients who are not eligible for a radical bladder resection or who have refused surgery.
- Patient who are not being pregnant or breast feeding until the study period.
Exclusion Criteria:
- Patient diagnosed with muscle-invasive bladder cancer at TURBT
- If upper urinary tract urothelial cancer is accompanied by imaging
- If the imaging indicates extravesical involvement (cT3)
- Imaging shows lymph node metastasis (short-axis 15mm or more) or distant metastasis
- In a biopsy, non-transitional cell histology is dominant, or only non-transitional cell tissue is present (primary squamous cell carcinoma, primary adenocarcinoma, small cell carcinoma, sarcoma, carcinosarcoma, paraganglioma, melanoma, lymphoma)
- In the case of receiving systemic cytotoxic chemotherapy for other cancers within 3 years
- If patient have a history of pelvic radiation therapy for other cancers within 3 years
- If patient have a history of receiving Mitomycin-c or gemcitabine in the bladder within 3 years. The exception is cases used for the purpose of injection therapy of anticancer drugs in the early bladder cancer
- If patient has a history of allergy to mitomycin-c or gemcitabine
- Cystoscopy shows a tumor in the prostate urethra
- Patients who have participated in studies using clinical trial drugs and are currently receiving clinical trial drugs or who have used clinical trial drugs or clinical trial medical devices within 4 weeks prior to the date of initial treatment
- After post-cystoscopy/TURBT, the patient received intravesical chemotherapy prior to the start of trial treatment
- Thrombocytopenia, coagulopathy or bleeding tendency patient.
- Pregnant or breast-feeding women
- If patient treated yellow fever vaccine or phenytoin
- Dysfunction of liver or kidney (GFP≤30)
- If patient undergo severe myelosuppression
- If patient complicated severe infection
- If patient definitely diagnosed interstitial lung disease or lung fibrosis by chest X-ray.
- If patient conduct chest radiotherapy.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Intervention group
Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml |
Intravesical instillation of Mitomycin-c 40 mg in 20 ml as the first agent in sequential treatment.
Andra namn:
Intravesical instillation of Gemcitabine 2000 mg in 50 ml following Mitomycin-c administration. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
High risk Recurrent free survival in sequential treatment group.
Tidsram: 1year
|
Time from initial TURBT* to first histologically confirmed recurrence of high-risk NMIBC or disease progression (per PFS definition), whichever occurs first. |
1year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression free survival in sequential treatment group.
Tidsram: 1year
|
defined as the period from the initial TURBT date* to the time when T stage progresses (e.g., Ta>T1, CIS>T1) (PFS1) or muscle invasive bladder cancer (T2 or higher) was first biopsy confirmed (PFS2) or imagingally diagnosed with metastasis to bladder cancer. |
1year
|
|
Cystectomy free survival in sequential treatment group.
Tidsram: 1year
|
Defined as the period from the initial TURBT date* to the time when radical cystomy was performed. |
1year
|
|
cancer specific survival in sequential treatment group.
Tidsram: 1year
|
Duration from initial TURBT date* to the time of death from bladder cancer |
1year
|
|
Overall survival in sequential treatment group.
Tidsram: 1year
|
The period from the initial TURBT date* to the point of death (regardless of cause) |
1year
|
|
Safety of sequential treatment.
Tidsram: 2year
|
The first safety analysis is conducted on test subjects who have developed toxicity in accordance with CTCAE standards. In particular, urinary disorders such as urinary tract infections and acute urination that occurred after injection of drugs into the bladder are evaluated. |
2year
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Ho Kyung Seo, MD, National Cancer Center, Korea
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Urologiska neoplasmer
- Sjukdomar i urinblåsan
- Neoplasmer i urinblåsan
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Förenad
- Deoxycytidin
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Kinoner
- Aziriner
- Mitomyciner
- Indolekinoner
- Gemcitabin
- Mitomycin
Andra studie-ID-nummer
- NCC2024-0026
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .